Page last updated: 2024-11-05

ticlopidine and Heart Defects, Congenital

ticlopidine has been researched along with Heart Defects, Congenital in 7 studies

Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.

Heart Defects, Congenital: Developmental abnormalities involving structures of the heart. These defects are present at birth but may be discovered later in life.

Research Excerpts

ExcerptRelevanceReference
"Testing platelet function makes clopidogrel dosing safer, and simplifies therapy adjustments in long-term treatment."2.77Prophylactic use of clopidogrel in paediatric cardiac patients. ( Grohmann, J; Hanke, CA; Nakamura, L; Stiller, B; Zieger, B, 2012)
"To review a pediatric experience with the antiplatelet agent clopidogrel and suggest a dosage regimen."1.33Clopidogrel use in children. ( Avner, M; Benson, LN; Finkelstein, Y; Koren, G; Nurmohamed, L, 2005)

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (42.86)29.6817
2010's4 (57.14)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Wessel, DL1
Berger, F1
Li, JS1
Dähnert, I1
Rakhit, A1
Fontecave, S1
Newburger, JW1
Wilson, SR1
Kronzon, I1
Machnicki, SC1
Ruiz, CE1
Maltz, LA1
Gauvreau, K1
Connor, JA1
Jenkins, KJ1
Abdulla, RI1
Gentilomo, C1
Huang, YS1
Raffini, L1
Hanke, CA1
Stiller, B1
Nakamura, L1
Grohmann, J1
Zieger, B1
Finkelstein, Y1
Nurmohamed, L1
Avner, M1
Benson, LN1
Koren, G1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
International Randomized Double Blind Study Evaluating the Efficacy and the Safety of Clopidogrel 0.2 mg/kg Once Daily Versus Placebo in Neonates and Infants With Cyanotic Congenital Heart Disease Palliated With Systemic to Pulmonary Artery Shunt[NCT00396877]Phase 3906 participants (Actual)Interventional2006-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participants According to Bleeding Type/Etiology

For all reported bleeding events, the type and the etiology of the bleeding event were collected. Participants who experienced bleeding events during the 'on-treatment period' were counted by bleeding type and etiology. Participants who had multiple bleedings could be counted several times. (NCT00396877)
Timeframe: From randomization up to 28 days after treatment discontinuation or final follow-up visit, whichever comes first

,
Interventionparticipants (Number)
SpontaneousPost-traumaticPuncture (vascular access site)Surgical
Clopidogrel 0.2 mg/kg/Day5611917
Placebo6061910

Number of Participants Reaching Primary Endpoint Criteria (First Occurrence of Death / Shunt Thrombosis / Cardiac Procedure < 120 Days Considered of Thrombotic Nature)

"The primary endpoint was the first occurence of any of the following events: Death (including heart transplant); Shunt thrombosis requiring intervention; Hospitalization for bi-directional Glenn procedure or any cardiac related intervention prior to 120 days of age following an event or a shunt narrowing considered to be of thrombotic nature by the blinded adjudication committee.~Only the first event was counted." (NCT00396877)
Timeframe: Median follow-up of 5.8 months (up to a maximum of 12 months after randomization)

,
Interventionparticipants (Number)
Death / Shunt Thrombosis / Cardiac Procedure- Death- Shunt thrombosis- Cardiac procedure <120 days of thrombotic nature
Clopidogrel 0.2 mg/kg/Day89512612
Placebo9060219

Number of Participants With Bleeding Events

"Bleeding events spanning from signature of the Informed Consent Form up to the last visit were collected as for any Adverse Event.~The 'on-treatment' period was defined as the period from randomization up until 28 days after treatment discontinuation or final follow-up visit, whichever came first, and participants who experienced bleeding events during that period were counted." (NCT00396877)
Timeframe: From randomization up to 28 days after treatment discontinuation or final follow-up visit, whichever comes first

,
Interventionparticipants (Number)
Any bleeding event- Serious- Serious with an outcome of death- Leading to permanent treatment discontinuation
Clopidogrel 0.2 mg/kg/Day873019
Placebo883219

Trials

2 trials available for ticlopidine and Heart Defects, Congenital

ArticleYear
Clopidogrel in infants with systemic-to-pulmonary-artery shunts.
    The New England journal of medicine, 2013, Jun-20, Volume: 368, Issue:25

    Topics: Anastomosis, Surgical; Clopidogrel; Double-Blind Method; Female; Follow-Up Studies; Heart Defects, C

2013
Prophylactic use of clopidogrel in paediatric cardiac patients.
    Klinische Padiatrie, 2012, Volume: 224, Issue:3

    Topics: Aspirin; Child; Child, Preschool; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combi

2012

Other Studies

5 other studies available for ticlopidine and Heart Defects, Congenital

ArticleYear
A constrained heart: a case of sudden onset unrelenting chest pain.
    Circulation, 2014, Oct-28, Volume: 130, Issue:18

    Topics: Analgesics, Opioid; Aspirin; Chest Pain; Clopidogrel; Coronary Angiography; Drug Therapy, Combinatio

2014
Clopidogrel in a pediatric population: prescribing practice and outcomes from a single center.
    Pediatric cardiology, 2009, Volume: 30, Issue:2

    Topics: Adolescent; Child; Child Welfare; Child, Preschool; Clopidogrel; Coronary Thrombosis; Drug Prescript

2009
Propagating knowledge: the value of the single center experience.
    Pediatric cardiology, 2009, Volume: 30, Issue:2

    Topics: Cardiology; Child; Child Welfare; Clopidogrel; Heart Defects, Congenital; Humans; Pediatrics; Ticlop

2009
Significant increase in clopidogrel use across U.S. children's hospitals.
    Pediatric cardiology, 2011, Volume: 32, Issue:2

    Topics: Adolescent; Child; Child, Preschool; Clopidogrel; Coronary Thrombosis; Databases, Factual; Drug Ther

2011
Clopidogrel use in children.
    The Journal of pediatrics, 2005, Volume: 147, Issue:5

    Topics: Adolescent; Cardiac Catheterization; Child; Child, Preschool; Clopidogrel; Drug Administration Sched

2005